A Randomized Double-Blind Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa
K
Kathy Miller, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
No Description Available
Description
No Description Available
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Breast Cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
25 Apr 2024.
Study ID: 0604-06 (1010002444)
